Cell therapies to save lives
CellProtect Nordic Pharmaceuticals AB develops innovative new cell therapies to treat severe diseases. The lead program is CellProtect drug candidate; ex vivo activated and expanded Natural killer (NK) cells for treatment of multiple myeloma. CellProtect Nordic Pharmaceuticals AB has established a protocol for expansion and restoration of cytotoxic activity of the NK cells, thereby offering patients a new and potentially curative treatment.
CellProtect is currently in Phase I clinical trials as adjunct treatment to autologous stem cell transplantation in patients with multiple myeloma. The Phase I study is conducted at the Karolinska University Hospital, Huddinge, Sweden.
CellProtect Nordic Pharmaceuticals AB is also a partner in the BOOSTB4 study funded through Horizon2020. BOOSTB4 is a research project which centers perform clinical studies with a novel stem cell treatment for the rare, congential disease osteogenesis imperfecta which causes repeated bone fractures and stunted growth.